Thieme E-Books & E-Journals -
Z Gastroenterol 2025; 63(08): e417-e418
DOI: 10.1055/s-0045-1810725
Abstracts | DGVS/DGAV
Kurzvorträge
Molekulare Therapie bei CED Donnerstag, 18. September 2025, 11:15 – 12:51, MZF 1

Efficacy and safety of subcutaneous guselkumab induction therapy in patients with ulcerative colitis: results through week 24 from the phase 3 ASTRO study

Authors

  • U Seidler

    1   Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Deutschland
  • M Long

    2   Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC, Vereinigte Staaten
  • J R Allegretti

    3   Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Vereinigte Staaten
  • S Danese

    4   Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italien
  • M Germinaro

    5   Johnson & Johnson, Spring House, PA, Vereinigte Staaten
  • T Baker

    5   Johnson & Johnson, Spring House, PA, Vereinigte Staaten
  • Y Alvarez

    5   Johnson & Johnson, Spring House, PA, Vereinigte Staaten
  • S Jorgens

    5   Johnson & Johnson, Spring House, PA, Vereinigte Staaten
  • L Jiang

    5   Johnson & Johnson, Spring House, PA, Vereinigte Staaten
  • H Zhang

    5   Johnson & Johnson, Spring House, PA, Vereinigte Staaten
  • T Hisamatsu

    6   Kyorin University School of Medicine, Tokyo, Japan
  • D T Rubin

    7   University of Chicago Medicine Inflammatory Bowel Disease Centre, Chicago, IL, Vereinigte Staaten
  • L Peyrin-Biroulet

    8   University of Lorraine, Inserm, NGERE; Groupe Hospitalier privé Ambroise Paré-Hartmann, Paris IBD Centre, Nancy / Neuilly sur Seine, Frankreich